

Technology for Mobility in SCI Ten Years From Now

Michael Boninger^{1,2,3}, Jennifer French⁴, James Abbas⁵, Laszlo Nagy⁶, Martin Ferguson-Pell⁷, Susan Johnson Taylor⁸, Mary Rodgers⁹, Norman Saunders¹⁰, Hunter Peckham^{11,12}, Ruth Marshall¹³, Art Sherwood¹⁴

¹ Department of Physical Medicine & Rehabilitation, Pittsburgh, PA

² UPMC Rehabilitation Institute, Pittsburgh, PA

³ Human Engineering Research Laboratories, VA Pittsburgh Healthcare System, Pittsburgh, PA

⁴ Neurotech Network, Tampa, FL

⁵ Center for Adaptive Neural Systems, School of Biological and Health Systems Engineering, Arizona State University, Tempe, AZ

⁶ Community Advisory Board, MetroHealth Rehabilitation Institute of Ohio, Cleveland, OH

⁷ Faculty of Rehabilitation Medicine, University of Alberta, Edmonton, AB

⁸ Rehabilitation Institute of Chicago, Chicago, IL

⁹ Department of Physical Therapy & Rehabilitation Science, University of Maryland School of Medicine, Baltimore, MD

¹⁰ Department of Pharmacology, University of Melbourne, Parkville, Australia

¹¹ Department of Biomedical Engineering, School of Medicine, Case Western Reserve University, Cleveland, OH

¹² Louis Stokes Cleveland VA Medical Center, Cleveland, OH

¹³ School of Medicine, Faculty of Health Sciences, University of Adelaide, Adelaide, Australia

¹⁴ National Institute on Disability and Rehabilitation Research, U.S. Department of Education, Washington, DC

Address all correspondence to:

Michael Boninger, M.D.

3471 5th Ave. Suite 201

Pittsburgh, PA 15213

boninger@pitt.edu

Ph: 412-648-6654 Fax: 412-692-4354

2 **Abstract**

3 *Objectives:* To identify technological advances that are likely to have a great impact on
4 the quality of life and participation in individuals with spinal cord injury (SCI).

5 *Methods:* In this paper we use the International Classification of Function to frame a
6 discussion on how technology is likely to impact SCI in ten years.

7 *Results/Conclusion:* While technology advances are exciting, a large challenge for the
8 research community will be how to effectively apply and deploy this technology.

9 Advances occurring in the next 10 years that reduce cost of technology may be more
10 important to the population with SCI than brand new technologies. Social context is
11 everything. As a research community we must advocate for better systems of care.

12 Advocating now for better care will lead to a world in 2020 that is ready to adopt new
13 technologies that are truly transformative.

14 *Keywords:* Spinal cord injury; mobility, assistive technology; International Classification
15 of Function

16

17

18 **Introduction**

19 The International Classification of Function defines mobility as “moving by changing
20 body position or location or by transferring from one place to another, by carrying,
21 moving or manipulating objects, by walking, running or climbing, and by using various
22 forms of transportation.”(1) Clearly this broad definition highlights the areas that can be
23 affected by paralysis and loss of sensation in individual with spinal cord injury (SCI).
24 Individuals with SCI and significant neurologic impairment are able to move through use
25 of technology such as wheelchairs, orthoses such as leg braces, and neuroprosthetic
26 functional electrical stimulation (FES) systems. Recovery of function is likely to be
27 impacted by technology such as robotic therapy devices. Thus current technologies
28 enable significant independence and participations. However there is also substantial
29 room for improvement. In this paper we discuss where we believe technology for
30 movement will be in approximately ten years, thus informing directions for future
31 research.

32

33 **Framework**

34 According to the International Classification of Function (ICF) framework a patient’s
35 level of disability is an interaction between their impairment and the environment.(1)
36 Technology impacts this in a number of ways. A robotic gait trainer can reduce
37 impairment and thus disability. A wheelchair makes it possible for an individual with
38 paralysis to traverse a sidewalk. FES can reanimate an arm to allow for object
39 manipulation. In this framework, technology has the potential to fully eliminate
40 disability (see figure 1). However, technology has not achieved that end goal.

41 Wheelchairs available on the market cannot traverse steps, FES devices do not allow an
42 individual to play a piano, and robotics do not result in full recovery.

43 Will technology allow complete independence someday? The answer is likely yes. How
44 will this come about? While research directly in the field of rehabilitation is essential, in
45 the technology realm, it is likely that breakthroughs in general technology will drive
46 improvement in technology for mobility. In ten years computers will be faster, power
47 supplies will last longer and deliver more power, all components will be smaller, and the
48 software that controls devices will be smarter. In addition the ability for machines to
49 interact directly with the body will improve through better sensing, biocompatibility and
50 integration with the nervous system.

51 All of these advances have the potential to greatly impact individuals with SCI, but
52 individuals with SCI frequently don't fully benefit from the technologic advances.

53 Economic reality often stifles research for products that would only benefit a relatively
54 small population. Even when large populations exist, such as all wheelchair users or all
55 individuals with upper limb impairment, the reimbursement of medical services or the
56 complexity of health systems across the world can prevent progress. Thus, when
57 discussing future technology, it is essential to look at social context. In this paper we will
58 review expected advances in specific areas of technology. We will then look at the
59 device level to project how these advances will impact rehabilitation and assistive
60 technology. Finally we will look at the social context of technology for mobility and how
61 the political, social and economic environment is likely to impact advances.

62 **Advances in Technologies**

63 *Power sources*

64 Power sources have advanced with higher capacity and lighter weight cells that are more
65 resilient to “abuse”. This has been driven largely by the demands of cell phones and
66 laptop computers. New technologies demand even greater capabilities including greater
67 capacity, extended periods between charges, longer life, and greater tolerance of over-
68 discharge. Even greater demands are created when the device is implanted in the body
69 with the consequences of failure amplified by replacement that requires surgical
70 intervention. Several approaches have been developed to address these challenges
71 including power supplied by inductive radio frequency (RF) coupling of power to the
72 implanted (and moisture protected) circuitry. This can be used as the direct power
73 source, eliminating the need for implanted batteries, or as the source to recharge an
74 implanted battery.

75 One may expect new technologies to provide a larger number of alternatives for power
76 sources. Already, lithium ion and similar chemistries have advanced to allow greater
77 capacity, an enhanced number of charge/discharge cycles, and discharging to zero charge
78 without damage to the cell. Looking further into the future, one can envision cells that
79 not only include new chemistries, but also entirely new concepts. Are implanted fuel
80 cells in our future? As our consumer demands on large power systems for automobile
81 propulsion enable clean power solutions, one can expect that some of these will be
82 applicable to power sources for SCI. What about cells recharged by the movement of the
83 body—a physiological recharging mechanism(2) or cells that can utilize the body’s own
84 chemistry to provide the power source to the cell. With the demands of a greater number
85 of portable consumer devices to drive them to smaller dimensions and lighter weight,
86 and the broader acceptance of implantable medical devices, clearly some of these
87 technologies will be realized in practical forms.

88 *Processing*

89 Moore's law predicts that the number of transistors that can be economically placed in a
90 processor will double every two years.(3) For the last 45 years, the semiconductor
91 industry has met this prediction. Advances in processor technology have provided us
92 with affordable laptops, mobile phones, digital cameras, HD TV's, internet
93 communication, and wireless routers. Perhaps more importantly, these advances have
94 enabled much of the progress in medical care that has occurred over the past several
95 decades. For individuals with disabilities, the independence provided by mainstream
96 technologies such as mobile phones, laptops and internet access is substantial. So, what
97 can we expect as an encore? First, we should ask: does it matter? Many of the advances
98 in rehabilitation technology that we can expect to see over the next decade may be
99 possible with microprocessors available today. Our primary challenge is to utilize these
100 fast, cheap and powerful processors to restore mobility with the next generation of
101 technology.

102 Some experts predict that Moore's law may hold only for another 5 years, so we will
103 have to look beyond the mainstream of the semiconductor industry for the next round of
104 advances in processors. We see at least three trends in processors that may enable
105 improved mobility for people with SCI. First, we will move beyond the binary realm of
106 the digital transistor. 'Neuromorphic' technology(4-6) uses paradigms that mimic
107 biological neurons in an attempt to gain some of the computational capabilities and
108 computational efficiencies of neurobiological systems. Second, we will have processors
109 that adapt to needs of the user. These adaptations may come about through
110 neuromorphic design or entirely different approaches, but they will enable autonomous
111 reconfiguration of the processor itself to improve processing speed, enhance processing
112 capability and/or reduce power consumption. Finally, we will have tools that will reduce
113 costs and improve the functionality of custom-designed processors. Engineering design

114 tools that enable rapid and cost-effective development of specialized microchips will
115 enable their utilization in small market technologies such as those for people with SCI.

116 *Sensors*

117 Sensors technology can be critical to movement in SCI. As an example position sensors
118 can provide a feedback loop necessary for high level control of a FES-power
119 neuroprosthesis.(7) Additionally sensors that can detect tissue hypoxia can alert an
120 individual with SCI to move as a means of preventing pressure sores.(8) Advances in
121 sensors over the next ten years will likely include an increased capacity to sense various
122 body stasis parameters noninvasively. There will also likely be an increased ability to
123 transfer this data in real time to widely distributed networks. GPS and ubiquitous camera
124 systems are likely to be able to provide additional information related to location and
125 position in the environment. Thus one could envision that in ten years wheelchairs will
126 incorporate GPS and sensor ability. The sensors will automatically trigger movement for
127 pressure sore prevention. Cameras could allow for collision avoidance so that individuals
128 who have limited motor function are safer while driving.(9;10) In addition smart clothing
129 based sensors will provide the feedback needed for high level closed loop control,
130 including temperature sensors, to avoid burning an insensate hand.

131 *Manipulators*

132 Manipulators or robotic arms represent a range of devices that have the potential to be
133 used by people with high level SCI to perform tasks. They can be attached to work-
134 surfaces or wheelchairs and have been produced commercially for nearly two decades.
135 (11;12)The limitation of most of these devices has been the need for extensive inputs
136 from the user, through devices such a ‘sip and puff’, and head or eye-tracking. This
137 limited input coupled with the multiple degrees of freedom of the manipulators makes

138 task performance very slow compared to typical function. Therefore manipulator or
139 robotic arm technology is more limited by the ability of a user to control the arm than the
140 technology to build the arm. Advanced machine vision systems, brain computer
141 interfaces, and shared control with a remote user, maybe the most important advances
142 that can be achieved. The advances that are likely to occur in manipulators will involve
143 greater dexterity of the “hand”, the inclusion of sensory feedback, and greater speed and
144 strength through miniaturized motors. It is likely that some of the DARPA-supported
145 advances related to the ongoing emphasis of prosthetic limb control will be applicable to
146 people with SCI. In the end, additional improvements are likely to be driven by
147 commercialization strategies that increase access to manipulator technologies. Advances
148 in many of the areas covered in this paper will be needed to drive complex manipulators.
149 For example, machine vision and “function-prediction” features involving artificial
150 intelligence will reduce the level of control required from the user.

151 *Algorithms – software*

152 ‘Graceful’ is a term that has rarely been used to describe the movements produced by a
153 neural prosthesis, an exoskeleton, or a semi-autonomous wheelchair; ‘robotic’ is a term
154 that has rarely been used to describe the movements of a cat. The cat has arrays of high
155 quality sensors for multiple modalities of information and has a set of strong and well-
156 controlled muscles. Most importantly, however, the cat utilizes highly evolved and
157 specialized algorithms to integrate information, plan movement and execute a
158 coordinated strategy. Over the next decade, we envision technology for mobility that is
159 safer, more highly functional, more energy efficient and more graceful. The pattern of
160 light that falls on a camera lens can be used to gather information about obstacles, the
161 pattern of forces on an insole sensor array can be used to monitor the progression of the
162 center-of-pressure during gait, and the pattern of torques generated by motors can

163 provide information about the actions of the exoskeleton. Integrating sensor information
164 across multiple modalities to plan a movement path or strategy provides an even greater
165 challenge. Advances in these areas will primarily be achieved through the development
166 of algorithms that are akin to those used by the cat and other biological systems.

167 ‘Biomimicry’ is an expanding branch of engineering that seeks to develop technology
168 that mimics biological systems.(13) Biomimetic sensors and biomimetic actuators will
169 play a role in improved systems for mobility, but perhaps the greatest advances will
170 come from the development of biomimetic algorithms – computations that mimic those
171 of the sensorimotor regions of the brain and spinal cord.(14) The combination of multi-
172 modal sensor fusion tactics and motor coordination strategies may ultimately produce
173 systems for mobility that deserve to be described as ‘graceful’.

174

175 **Impact on specific devices**

176 *Robotics*

177 For the purpose of this paper, rehabilitation robotics for mobility can take two roles.
178 Rehabilitative robotics can help the individual with SCI regain function. Two current
179 examples include robotic treadmill ambulation devices and robotic upper limb retraining
180 devices.(15) Research has found that repetitive movement can enhance the return of
181 motor function. These exoskeletally applied rehabilitative robotics are ideally suited to
182 this role and have the added benefit of measurable outcomes, a critical issue in
183 healthcare. Most rehabilitation robotics use computer feedback or a virtual reality type
184 environment to give the user feedback in a gaming environment. In the future, these
185 relatively simple exoskeletally applied devices are likely to become more complex,
186 allowing for greater freedom to received assistance during an actual task. At the same

187 time they will likely be able to measure the amount of assistance provided and adjust
188 their rehabilitation regimen in subtle ways. As these tools become more widespread, the
189 cost is likely to decrease and the proliferation of these devices is likely to occur.

190 In addition, assistive robotics can theoretically provide direct assistance with activities of
191 daily living. Assistive robotics have significantly more technical hurdles to overcome to
192 become truly functional. Technical hurdles include the ability to move around in a
193 changing environment autonomously. This is an intense challenge in the robotic realm.
194 Simply picking up objects and being able to adequately manipulate them for functional
195 uses is challenging. Above all else safety must be maintained, which requires that the
196 robots operate with extreme precision not needed in other applications. Advances in the
197 technical areas listed above are likely to hasten progress in assistive robotics and in the
198 meantime simple robotics as part of other devices (smart wheelchairs – see below) are
199 likely to predominate in rehabilitation.

200 *Exoskeletons*

201 Born out of military and space applications to enhance performance on the battlefield
202 and in space, respectively, exoskeletons have a place in the rehabilitation market for SCI.
203 In general, the term 'exoskeleton' is used to describe a device that is external to the body,
204 like a brace. But unlike a brace, augments the performance(16) through actuators. Many
205 exoskeletal systems have been developed to augment function, but have yet to gain wide
206 spread use. This is largely due to the size and weight of current systems and to
207 difficulties with performance in the natural environment. Exoskeletons as devices to
208 improve rehabilitation, like the robotic treadmills have gained some acceptance. New
209 developments in hydraulic actuators, battery power, sensory circuitry and materials are
210 likely to turn the exoskeleton of the future into more of a 'Second Skin Space Suit', as

211 military focus on such developments will have spinoffs to people with disabilities. The
212 devices will be customizable to the needs and anatomy of the user, sensing and
213 compensating for fatigue and worn inconspicuously under common clothing. By 2024,
214 people will walk down streets, in malls and home bearing exoskeletons. Rehabilitation
215 will have an assortment of them available to aid people with SCI, some as assistive
216 technology to wear for walking and some for rehabilitation in the clinic.(17)

217 *Wheelchairs*

218 At present, wheelchairs are the most important mobility technology for individuals with
219 SCI and are likely to remain so for at least the next decade. The evidence that
220 wheelchairs impact quality of life is overwhelming.(18) Yet in the last decade design
221 improvements in wheelchairs can be described as “incremental”. Changes in the next
222 decade in manual wheelchairs will likely be dictated by improvements in materials and
223 manufacturing that will drive down the weight and increase the ease of mobility and
224 customizability of chairs. Mobility control will be greatly impacted by advances in
225 machine vision that will allow autonomous navigation. Advances in virtual reality will
226 allow better training. Software and microprocessor advances will allow for smarter
227 joysticks that will enable even those with the most severe motor impairments to use this
228 control and in the absence of any motor input brain computer interface (BCI) will allow a
229 user to think and control the wheels. The power wheelchair itself will involve greater
230 sensing and flexibility allowing it to traverse significant environmental barriers and very
231 rough terrain. In addition, the wheelchairs will be able to sense aspects of the driver’s
232 well being and automatically call for help, or shift seat configuration to prevent pressure
233 sores. Although it is possible that advance in other areas, like exoskeletons, will
234 eventually render the wheelchair as we know it obsolete, this is unlikely to happen in the
235 next ten years making continued research essential. Furthermore, there is a significant

236 challenge in seeing these advances adopted by manufacturers who are challenged with
237 decreasing reimbursement and manufacturing facilities that are not setup to incorporate
238 new high tech materials.

239 *Direct Brain Interfaces*

240 Direct Brain Interfaces (DBI or Brain Machine Interfaces) refer to a direct access to brain
241 signals for the purpose of controlling a device or receiving sensory feedback.(19) At
242 present there is significant study in this area as it relates to SCI. DBI have the theoretical
243 benefit of offering virtually unlimited control signals using thought to operate a device.
244 Current major hurdles for DBI are related to biocompatibility and stability of electrodes
245 that penetrate the brain, achieving maximal degrees of freedom from the implanted
246 device, and providing sensory input that is needed for higher levels of control. Even with
247 these barriers investigators have achieved multiple degree of freedom control in non-
248 human primate studies and in human studies.(20;21)

249 It seems likely that higher degrees of motor control will be achieved in humans in the
250 next 10 years and that a clinically viable product will be available. Creating a stable
251 interface will likely still be the subject of investigation for electrodes that penetrate the
252 brain. However, non-penetrating electrodes (known as ECoG) may achieve high degree
253 of freedom control and be a stable long term solution. Providing the high level sensory
254 feedback needed for closed loop control will likely still be the subject of much research
255 and the interaction of the brain and the interface to achieve maximal neuroplasticity will
256 likely be studied for decades.

257 *Neural Prostheses*

258 Neural prostheses (NP) can increase the function of people with SCI providing the ability
259 to use paralyzed hands, breath independently, improving bowel and bladder function and

260 trunk control.(22;23) Currently, these functional enhancements are each provided with
261 individual devices. In the near future a multifunctional networked device will enable a
262 network of sensing and actuation (stimulation) power and control modules to be
263 distributed throughout the body in the regions of the target organs. This will allow
264 scalability and has the potential of enabling a user to have many body functions restored
265 with a single device. NP function also will be impacted by other advances in electrodes,
266 sensors, power supplies, cellular therapies as well as techniques to modify the function of
267 neural circuitry. Despite strong performance, NP technology is not widely available. This
268 demonstrates the challenges of bringing class III technologies onto the commercial
269 market in small populations such as SCI.

270 *Neuromodulation and drug delivery*

271 Although biologically driven neuro-repair is not the focus of this paper, advances in
272 technology are likely to drive this area and warrant discussion. A critical aspect of
273 recovery of movement after SCI is central nervous system neuroplasticity. Neuroplastic
274 changes can be influenced both by the environment and activity which can be
275 manipulated through interventions ranging from activity-based therapy(24;25) to
276 electrical stimulation(26) to cellular implants, to local or systemic application of various
277 substances. Here we focus on neuromodulation via electrical stimulation and via
278 chemical agents. By 2020, delivery systems will be available at a scale appropriate to the
279 job, from macro down to nanoscale.(27;28) Indeed, there are already movements from
280 macro to micro in electrodes.(29) Similarly, progress is being made in developing new
281 drug delivery systems, from the current macro system implantable pumps, to drug
282 infusion patches, to encapsulation of drugs in nano-sized carbon buckyballs and
283 nanotubes permitting delivery even across the blood-brain barrier.(30)

284 Technical challenges in creating such technologies can be confidently predicted to be
285 overcome; however, knowing where and how to stimulate (electrical) or what substances
286 to deliver at what rates, and the means of directing these devices to those targets, pose
287 the rate limiting factors in employment of this new technology. Neuromodulation is
288 likely to be used to augment gait therapy for example, where it could facilitate the
289 lumbar pattern generator, thus promoting ambulation. In terms of impact on
290 rehabilitation, it can be anticipated that deployment of these approaches will not be in the
291 nature of the *Fantastic Voyage* (1966), but rather will be commonly utilized in a
292 rehabilitation setting in coordination with targets autonomously acquired using
293 chemoattractors and magnetic field manipulation.

294 *Virtual Reality*

295 Simulation and virtual reality (VR) hold the promise to assist in achieving greater
296 mobility in a wide range of activities such as walking(31) and driving.(32) In addition,
297 VR can be used to improve social integration, state of health, morale and self esteem
298 through virtual sport.(33;34) There is a critical difference between systems that use VR
299 only and those that link VR to physical simulation of a real-life activity such as walking,
300 driving or sailing. VR that uses bodily responses can be fun and motivating, and can be
301 structured to provide progressive challenges thus increasing motor skills as rehabilitation
302 progresses.(35) In 10 years VR will likely be less expensive, more immersive, and better
303 able to respond to any biologic signal such as BCI.(36) VR in one form or another will
304 likely be a normal part of rehabilitation, increasing the fun of repetitive movement and
305 motivating patients. Research in 2020 is likely to involve the best way to use this
306 potentially potent tool from a neuroplasticity, motivation and motor recovery
307 perspective.

308

309 **Potential impact on individuals with SCI**

310 *Impact on movement in ICF framework*

311 The International Classification of Functioning, Disability and Health (ICF) was
312 developed by the World Health Organization with the overall aim of providing a unified
313 and standard language and framework for the description of health and health-related
314 states.(1) It uses detailed accounts of a variety of impacts on daily living and quality of
315 life, for example, which can thoroughly classify an individual with more than one
316 condition. The model also accounts for a treatment shift from simple diagnosis by
317 observation to a diagnosis not only of the condition but also the impact on body
318 structure. As related to SCI, the ICF model defines mobility very specifically, not
319 leaving this to interpretation by regulators, third party payers or policymakers.

320 Since its creation, the implementation of the ICF model has been limited. The model
321 uses a matrix to compare domains versus qualifiers of performance and capacity. This
322 classifies an individual in great detail making it difficult to adopt in the clinical
323 environment. In the future, a training module or computer algorithm may be developed
324 to create a deployment tool for practicing clinicians and third party payers to quickly and
325 simply apply the model. As the ICF model relates to the application of technology to
326 overcome a disability, the classification may demonstrate the user's improved
327 performance even though limitations in capacity still exist. More widespread use of the
328 ICF model will improve our ability to assess the effectiveness of technology as it relates
329 to daily functioning and allow for a common language across world health systems.

330 *Barriers to deployment*

331 It is paramount that the scientific process leads to an influential end result for the user.
332 Perpetual research that yields nothing to benefit the consumer can be considered by
333 many to be a waste of money and time. There are three main barriers to deployment of
334 technologies for mobility; 1) market availability, 2) awareness and 3) financial access or
335 cost. Market availability has several components including technology transfer,
336 commercial intent early in the development process and technology evolution for
337 commercialization. Awareness includes not only the person with an SCI, but caregivers
338 and clinicians. In clinical practice the integration of technology should be part of the
339 standard of care. These barriers must be considered early when designing new
340 technology. Inclusion of end users with SCI throughout the process can help reduce
341 barriers. While these issues are current, they are unlikely to change and may become
342 more challenging over the next 10 years.

343 Financial access or cost relates to the design of useable technologies that are affordable
344 to the diverse world health systems including third party payers, government programs
345 and out of pocket purchases. Inevitably, prototypes cost more than marketable
346 technology; however innovation must lead to affordable end products. If researchers are
347 overly concerned about cost engineering, many of the developments discussed above
348 will not come to fruition and great advances will not occur. But researchers must not
349 ignore cost decisions when developing products. Although the costs may be high for
350 many technologies, the impact is substantial and can be available over the full life of the
351 individual. Thus, the Quality of Life Years that are provided by technologies for people
352 with SCI will be a significant argument to be promoted to gain acceptance by payers. A
353 major challenge will be to develop delivery models that ensure that when regulatory
354 approvals are received, that it is sustainable both clinically and financially.

355 If third party payers do not approve a device it will only be available to the wealthy and
356 will likely fail for lack of a market. Companies with great ideas have gone out of
357 business, because their products could not be coded and reimbursed. Independence
358 Technology, a J&J company, was founded to market and sell the innovative wheelchair
359 known as the IBOT™.(37) The IBOT™ incorporated gyroscopes that allowed it to
360 balance on two wheels, go over rough terrain and up stairs. These features are listed
361 above as futuristic. However, the device was deemed not medically necessary and the
362 absence of a successful reimbursement model led to a failed product.

363 Fortunately the cost of technology is decreasing. This trend is likely to continue through
364 2020 opening new possibilities. While research progresses in new technologies it is
365 essential that cost benefit models be explored that document the added medical and
366 functional impact of products. At the same time research must advocate for the broader
367 ICF view of participation instead of a narrow focus of “medical necessity”. What needs
368 to be elucidated is the cost for an individual and society if the enabling technology is not
369 provided. In 2020, it may not be justifiable to deny technology on the basis of
370 affordability, particularly if the provision of an item allows an individual to become a
371 valued member of society.

372

373 **Conclusion**

374 Technology holds great promise to ameliorate disability and allow for full participation
375 for individuals with SCI. However a few themes emerge as one follows where
376 technology for mobility research is likely to be in 2020. While technology advances are
377 exciting, a large challenge for the research community will be how to effectively apply
378 and deploy this technology. It is not how we design the latest rehabilitation robot, but

379 how we use it to enhance the lives of people with SCI. Technology is likely to put
380 amazing tools at the fingertips of clinicians, but if it is not properly implemented, they
381 may be discarded. In addition, if during technology development, research has not
382 effectively shown the value of the product, it will not be accepted by third party payers.
383 These issues require imaginative approaches, not just to the development of
384 technologies, but to the proof of their efficacy. Given the size of the population with SCI,
385 greater national and international collaborations will be needed than ever before to
386 develop the studies needed to prove efficacy.

387 A second theme is cost. Advances occurring in the next 10 years that reduce cost of
388 technology will likely be more important to the population with SCI than brand new
389 technologies. The affordability of mobile communication has arguably done more for the
390 safety of this population than any device research has developed. Advances that have
391 commercial appeal and can sell to mass market will lower prices and open the
392 technology up to the community with SCI. The assistive technology researchers of 2020
393 will need to take advantage of reduced costs and address the commercial viability of their
394 inventions, not just for an initial target population of SCI, but for a broader marketplace.

395 Finally, social context is everything. If the 2020 researcher develops a great product but
396 health care systems do not support its use, a life's work could be wasted. In addition,
397 advances in genetics and stem cells could be legislated against if not politically
398 acceptable. As a research community we must advocate for better systems of care now.
399 In addition we must pay attention to the social and political climate in which we work. If
400 we wait for 2020 it is unlikely that the products developed at that time will ever sell. This
401 advocacy cannot just stop in our own country. It must extend beyond individual borders
402 and determine how we impact the world population with SCI. Advocating now for better

403 care will lead to a world in 2020 that is ready to adopt a new technology that is truly
404 transformative.

405

406 **Conflict of Interest Statement**

407 The authors declare no conflict of interest.

408 The contents of this paper do not represent the views of the Department of Veterans
409 Affairs or the United States Government.

410

411

412

413

Reference List

414

415 (1) International Classification of Functioning. World Health Organization . 1-1-2007.

416 World Health Organization. 1-3-2011.

417 Ref Type: Electronic Citation

418 (2) Donelan JM, Li Q, Naing V, Hoffer JA, Weber DJ, Kuo AD. Biomechanical energy

419 harvesting: generating electricity during walking with minimal user effort. *Science* 2008;

420 **319**: 807-810.

421 (3) Moore G. Cramming more components onto integrated circuits. *Electronics* 1965;

422 **38**: 114-117.

423 (4) Mead C. Neuromorphic Electronic Systems. *Proceedings of the IEEE* 1990; **78**:

424 1629-1636.

425 (5) Jung R, Brauer EJ, Abbas JJ. Real-time interaction between a neuromorphic

426 electronic circuit and the spinal cord. *IEEE Trans Neural Syst Rehabil Eng* 2001; **9**: 319-

427 326.

428 (6) Sarpeshkar R. Ultra Low Power Bioelectronics: Fundamentals, Biomedical

429 Applications, and Bio-inspired Systems. New York: Cambridge University Press, 2010.

- 430 (7) Strange KD, Hoffer JA. Restoration of use of paralyzed limb muscles using sensory
431 nerve signals for state control of FES-assisted walking. *IEEE Trans Rehabil Eng* 1999;
432 **7**: 289-300.
- 433 (8) Jan YK, Brienza DM, Boninger ML, Brenes G. Comparison of skin perfusion
434 response with alternating and constant pressures in people with spinal cord injury. *Spinal*
435 *Cord* 2011; **49**: 136-141.
- 436 (9) Rentschler AJ, Simpson R, Cooper RA, Boninger ML. Clinical evaluation of Guido
437 robotic walker. *J Rehabil Res Dev* 2008; **45**: 1281-1293.
- 438 (10) Fioretti S, Leo T, Longhi S. A navigation system for increasing the
439 autonomy and the security of powered wheelchairs. *IEEE Trans Rehabil Eng* 2000; **8**:
440 490-498.
- 441 (11) Laffont I, Biard N, Chalubert G, Delahoche L, Marhic B, Boyer FC et al.
442 Evaluation of a graphic interface to control a robotic grasping arm: a multicenter study.
443 *Arch Phys Med Rehabil* 2009; **90**: 1740-1748.
- 444 (12) Bach JR, Zeelenberg AP, Winter C. Wheelchair-mounted robot
445 manipulators. Long term use by patients with Duchenne muscular dystrophy. *Am J Phys*
446 *Med Rehabil* 1990; **69**: 55-59.
- 447 (13) Bar-Cohen Y. Biomimetics: Biologically-Inspired Technologies. Boca
448 Raton, FL: CRC Press, 2006.
- 449 (14) Abbas JJ, Abraham A. Biomimetic Approaches to Physiological Control. In:
450 Bronzino JD, editor. *The Biomedical Engineering Handbook*. Boca Raton, FL: CRC
451 Press, 2011.

- 452 (15) Hesse S, Schmidt H, Werner C, Bardeleben A. Upper and lower extremity
453 robotic devices for rehabilitation and for studying motor control. *Curr Opin Neurol*
454 2003; **16**: 705-710.
- 455 (16) Herr H. Exoskeletons and orthoses: classification, design challenges and
456 future directions. *J Neuroeng Rehabil* 2009; **6**: 21.
- 457 (17) Ferris DP. The exoskeletons are here. *J Neuroeng Rehabil* 2009; **6**: 17.
- 458 (18) Chaves ES, Boninger ML, Cooper R, Fitzgerald SG, Gray DB, Cooper RA.
459 Assessing the influence of wheelchair technology on perception of participation in spinal
460 cord injury. *Arch Phys Med Rehabil* 2004; **85**: 1854-1858.
- 461 (19) Berger S, King EC. Designing services for the elderly. *AORN J* 1990; **51**:
462 448, 450, 452-448, 450, 454.
- 463 (20) Allen JB. Sports medicine and sailing. *Phys Med Rehabil Clin N Am* 1999;
464 **10**: 49-65.
- 465 (21) Velliste M, Perel S, Spalding MC, Whitford AS, Schwartz AB. Cortical
466 control of a prosthetic arm for self-feeding. *Nature* 2008; **453**: 1098-1101.
- 467 (22) Peckham PH. Restoration of function: current challenges and future
468 opportunities through electrical stimulation. *J Rehabil Res Dev* 2001; **38**: xiii-xxvi.
- 469 (23) Peckham PH, Knutson JS. Functional electrical stimulation for
470 neuromuscular applications. *Annu Rev Biomed Eng* 2005; **7**: 327-360.

- 471 (24) Sadowsky CL, McDonald JW. Activity-based restorative therapies: concepts
472 and applications in spinal cord injury-related neurorehabilitation. *Dev Disabil Res Rev*
473 2009; **15**: 112-116.
- 474 (25) Dobkin B, Barbeau H, Deforge D, Ditunno J, Elashoff R, Apple D et al. The
475 evolution of walking-related outcomes over the first 12 weeks of rehabilitation for
476 incomplete traumatic spinal cord injury: the multicenter randomized Spinal Cord Injury
477 Locomotor Trial. *Neurorehabil Neural Repair* 2007; **21**: 25-35.
- 478 (26) Kaplan HM, Loeb GE. Design and fabrication of an injection tool for
479 neuromuscular microstimulators. *Ann Biomed Eng* 2009; **37**: 1858-1870.
- 480 (27) Allen JB, De Jong MR. Sailing and sports medicine: a literature review. *Br J*
481 *Sports Med* 2006; **40**: 587-593.
- 482 (28) Andrews RJ. Neuroprotection at the nanolevel--Part I: Introduction to
483 nanoneurosurgery. *Ann N Y Acad Sci* 2007; **1122**: 169-184.
- 484 (29) Perlin GE, Wise KD. A compact architecture for three-dimensional neural
485 microelectrode arrays. *Conf Proc IEEE Eng Med Biol Soc* 2008; **2008**: 5806-5809.
- 486 (30) Allen JB, De Jong MR. Sailing and sports medicine: a literature review. *Br J*
487 *Sports Med* 2006; **40**: 587-593.
- 488 (31) Riva G. Virtual reality in paraplegia: a VR-enhanced orthopaedic appliance
489 for walking and rehabilitation. *Stud Health Technol Inform* 1998; **58**: 209-218.
- 490 (32) Ku J, Jang D, Ahn H, Lee J, Kim JA, Lee B et al. The development and
491 clinical trial of a Driving Simulator for the handicapped. *Stud Health Technol Inform*
492 2002; **85**: 240-246.

- 493 (33) Allen JB, De Jong MR. Sailing and sports medicine: a literature review. *Br J*
494 *Sports Med* 2006; **40**: 587-593.
- 495 (34) Chen CH, Jeng MC, Fung CP, Doong JL, Chuang TY. Psychological
496 benefits of virtual reality for patients in rehabilitation therapy. *J Sport Rehabil* 2009; **18**:
497 258-268.
- 498 (35) Steffin M. Virtual reality therapy of multiple sclerosis and spinal cord injury:
499 design consideration for a haptic-visual interface. *Stud Health Technol Inform* 1997; **44**:
500 185-208.
- 501 (36) Marathe AR, Carey HL, Taylor DM. Virtual reality hardware and graphic
502 display options for brain-machine interfaces. *J Neurosci Methods* 2008; **167**: 2-14.
- 503 (37) Cooper RA, Boninger ML, Cooper R, Dobson AR, Kessler J, Schmeler M et
504 al. Use of the Independence 3000 IBOT Transporter at home and in the community. *J*
505 *Spinal Cord Med* 2003; **26**: 79-85.
- 506
- 507

Figure Legend

Figure 1: International Classification of Function (ICF) based model for the paper. The frame of the picture represents the social context that will impact utilization and development of new technology. Along the top are the ICF related functions likely to be impacted by technology advances. Beneath ICF functions are the specific technologies that will impact devices, which are listed down the right side. At the center of it all is the person with a SCI.

Figure 1

